Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

Using a more pragmatic classification system than the current standard provided clearer discrimination between disease ...

The largest US study to date on teen cannabis uses shows that cannabis use during adolescence may hinder cognitive improvement over time.

A study from a single medical center in California has observed a nearly 15% prevalence of methamphetamine use in patients presenting with acute coronary syndrome.

Wheat allergy in young children is uncommon, but many referred children tolerate wheat protein or have a reaction only to ...

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...

Recent data from a single-arm trial suggest favorable-risk patients with HPV-associated oropharyngeal carcinoma may benefit from a deintensified regimen.

To have a drug that has an impact on mortality, it’s of huge interest and a benefit for patients with ILD,’ said rheumatologist Voon Ong, MBBS, PhD, who was not involved in the study.

Risk-enhancing factors are highly prevalent in adults without atherosclerotic cardiovascular disease and strongly linked to statin use in those at high risk for the condition.

People who do not have enough food to eat or who live below the poverty level are more likely to develop MASLD, and this risk ...